This document provides an overview of essential drugs and the World Health Organization's (WHO) model list of essential medicines. It discusses the history and definition of essential drugs, as well as the criteria and guidelines for establishing a national essential drugs program. Key points include: - The concept of essential drugs was developed in 1975 to improve access to necessary medicines in developing countries. The first WHO model list was published in 1977. - Essential drugs are those that satisfy the health care needs of most of the population and are available at all times. Selection is based on disease prevalence, treatment resources, and financial constraints. - Establishing a national essential drugs program requires designating a drug authority, developing treatment guidelines and form

1. ESSENTIAL DRUGS
Presented by;
Aiswarya.A.T
First year M.Pharm
Dept. of Pharmacy Practice
Grace College of Pharmacy

2. Essential drugs
HISTORY
In 1975, the 28th World Health Assembly reviewed the main drug problems
facing the developing countries & outlined possible new drug policies
The Director General of WHO, referred to the experience gained by some
countries, where schemes of basic or essential drugs had been implemented with
tremendous success
Such schemes were intended to extend the accessibility & rational use of most
necessary drugs to their respective populations, whose basic health needs could
not be met by the existing supply systems
The concept of essential drugs was born, & the first model list of essential drugs
was published in 1977

3. Current versions
18th WHO Essential Medicines List in
April 2013
4th WHO Essential Medicines List for
Children updated in April 2013
19th WHO Model List of Essential
Medicines in April 2015

4. WHO Definition
Essential drugs are those that satisfy the health
care needs of the majority of the population which is
available at all times in adequate amounts & in
appropriate dosage forms.
The model list of essential drugs is important in developing
countries because of the reasons:
Development of treatment guidelines
Development of national formularies
Measures to improve drug use information for patients & general
public

5. Guidelines For Establishing A National
Programme For Essential Drugs
A national drug authority should be established
A National Drugs & Therapeutics Committee (NDTC) should be
established
Generic names should be used for all drugs
A concise, accurate & comprehensive drug information booklet
should be prepared
The quality of all products, including stability & bioavailability
should be assured throughout product registration process

6. Competent health authorities should decide on the level of
expertise needed to prescribe drugs
Efficient administration of supply, storage & distribution of drugs
in the essential drug list, is indeed required for the success of ED
programme
There should be a well-documented procurement policy, based on
records of turnover of drugs
Research, both clinical & pharmaceutical, is sometimes needed to
settle a choice of a particular drug under local conditions
Guidelines … contd…

7. Criteria For The Selection Of Essential Drugs
Choice of essential drugs depends on many factors like;
Pattern of prevalent diseases in the country
Treatment facilities available
Level of training & experience of the personnel, who will
actually handle the drugs
Financial resources available in the country
Genetic, demographic & environmental factors

8. Selection of essential drugs must
always be;
Evidence-based; not situation based
Selected drugs should have sound & adequate data on their
efficacy & safety, based on clinical studies
Performance of a drug in general use has been proved in variety
of medical settings
Each selected drug must be available in adequate quantities & in
the dosage form that is recommended by NDTC
It must have assured quality, including bioavailability & stability,
under various conditions prevailing in the country

9. When 2 or more drugs appear to be similar in quality,
bioavailability, stability, choice should be made on the basis of
careful evaluation of their relative efficacy, safety, quality, price &
availability
When cost becomes an issue in the selection of drugs, only the unit
cost of the drug alone should not be considered
Comparative pharmacokinetic properties of drugs in the same
therapeutic category, proves helpful for the choice
Local facilities to manufacture drugs or their storage should also
be considered
ED’s should contain only one single basic drug or active ingredient
Contd…

10. Tasks After The Formation Of
Essential Drug List
1. Updating the ED list
Guiding principles have been laid down by WHO:
The extend to which the countries implement schemes, or
establish EDL is a national policy decision of each country
EDL must accommodate a variety of social situations to meet the
real health needs of the majority of the population
The model EDL is a tentative identification of ‘common core’ or
‘common thread’ which runs across health care needs of many a
developing country
Exclusion from model EDL doesn’t mean rejection
The formation of EDL & its updating is a continuing process

11. 2. EDL for primary health care centres
Existing system of medicines
National Health Infrastructure
The pattern of endemic diseases
Supplies

12. 3. Specialist control of drug use
Egs of situations where specialist control of drug use is necessary
are;
The use of reserve antimicrobials (antibiotics) for multiresistant
bacteria
Establishing adequate regimens for treatment of TB & leprosy
The use of antineoplastic & immunosuppressive drugs
The use of antiretroviral (AIDS) drugs
The use of antimicrobial, antifungal, antiviral agents for TB
treatment, respiratory infections of HIV positive & AIDS patients,
who are highly susceptible to such infections.

13. 4. Research & Development
a) Pharmaceutical aspects
Development of local or regional capacities in quality assurance, inorder to
ensure that quality is maintained.
Development of procurement procedures, especially for large quantities, to
get best price.
Development of processing & packaging of dosage forms, to ensure quality of
products.
Development of efficient distribution systems with suitably trained personnel
b) Clinical & Epidemiological aspects
To assess efficacy & safety of new candidate drugs
To assess benefits & safety of traditional medicines & medicinal plants in the
region
To assess effects of genetic & ethnic differences among local population on the
pharmacokinetics & other therapeutic parameters

14. c) Educational aspects
Development of training programmes in policy formation, quality
control, information system, drug procurement, storage &
distribution aspects.
Development of educational & training programmes for
prescribers & other healthcare workers.
Development of appropriate public education programmes,
information programmes on diagnosis, early recognition of
symptoms & use of correct self medication.
Development of information booklets & leaflets for consumer
education.

15. 5. Drug information & educational activities
For safe, effective & prudent use of ED, relevant & reliable drug
information is a must.
Make effective use of several WHO publications on “model
prescribing information”. Already five titles on drugs in
anaesthesia, parasitic diseases, mycobacterial diseases, STD’s& in
skin diseases, exist.
Develop model formulary to complement model list of ED’s.
Develop drug information sheets on all drugs in EDL, to guide
the prescribers to safe & effective use of drugs.

16. 6. Making a list of reserve Antimicrobials
Antimicrobial agent Specific indications in which to be used
Amoxicillin plus
Clavulanic acid
Beta lactamase inhibitor- producing bacteria.
To be used in polymicrobial infection related to surgical conditions
of intestinal or female genital tract
Ceftriaxone Treatment of meningitis due to Streptococcus pneumonia
Should not be used as chemoprophylaxis
Ceftazidine Use only when prevalence of resistance to gentamycin is high &
confirmed
Imipenme plus
Cilastatin
Use only for the treatment of Acinetobacter spp. Infection &
Pseudomonas spp resistance. These organisms are usually found in
ICU’s where use of prophylactic antibiotics is high
Ciprofloxacin & Other
Fluoroquinolones
Use for typhoid fever, severe shigellosis, gonorrhea, hospital
acquired infections of E.coli, P.aeroginosa
Vancomycin For use against methicillin-resistant Staph. aureus strains which are
resistant to all beta lactum antimicrobials & other antibiotics like
erythromycin, clindamycin, & chloramphenicol
Artemisin & its derivatives For patients with falciparum malaria, resistant to chloroquine
derivatives, sulphadoxine, plus pyrimethamine, mefloquine or
quinine are used

17. 7. Post- Registration drug studies
Although the EDL is made out all due considerations & extensive data including
clinical trial data, on the drugs included, there will be occasions, when drugs
used in practice will fail to produce benefit that was expected out of it.
The reasons are;
Clinical trials do not include groups like children, pregnant
women, old people
Genetic & environmental factors differ from population to
population
Data on overdose or longer term medication of the drug are
usually not available
Unexpected use of the drug, other than for what it was meant to
be used
Poor manufacturing practices in some countries which may lead
to poor dissolution & ultimately poor bioavailability

18. Thank you!